Charlie v. McKinsey & Company Canada
Consumer Protection Class Action
What this class action is about
Goldblatt Partners LLP and Sotos Class Actions have commenced a class action lawsuit against global consulting firm McKinsey & Company for its role in fuelling the opioid epidemic in Canada. The class action names McKinsey’s Canadian and US arms as defendants.
The representative of the class, Jordan Francis Charlie, a resident of Northern Ontario, was first prescribed OxyContin in 2007 due to a back injury sustained while working in forestry. Mr. Charlie soon developed a devastating addiction to opioids.
In 2021, McKinsey & Company reached a roughly $596 million-dollar settlement with attorneys-general in multiple US states. The settlement was reached after McKinsey’s extensive role in pushing the sale of OxyContin by Purdue Pharma L.P. was disclosed. Purdue has since filed for bankruptcy protection.
The class action seeks damages for the alleged negligence of McKinsey, breaches of consumer protections statutes, conspiracy, health care costs and unjust enrichment. The proposed class to be covered by the lawsuit generally consists of all persons resident in Canada who were prescribed opioids and who subsequently developed an addiction to opioids between 2002 and the date the class action is certified.